Mumbai, January 19, 2018: Panacea Biotec has signed two long term agreements with Serum Institute of India (SII) and SII’s wholly owned subsidiary, Bilthovan Biologicals B.

Under the collaboration, SII is entitled to manufacture and sell fully liquid whole cell pertussis (wP) and salk based injectable polio vaccine (IPV) based hexavalent vaccine developed and commercialised by Panacea Biotec, a first of its king in this category.

Under the collaboration, Serum Institute of India will ensure supply of IPV bulk to Panacea Biotech, an important constituent of the Hexavalent vaccine, from its wholly owned subsidiary BBIO, a bioengineering and pharmaceutical company, registered in the Netherlands having technology and expertise for making the IPV, earlier possessed by only 3 other vaccine manufacturers in the world.

Our Partners

The Pharma Times provides with the latest breaking news and videos straight from the Pharma industry including in depth coverage, news, views, reviews market dynamics, research and design of this industry.